Literature DB >> 1934622

Idiotypic and immunochemical differences of anti-DNA antibodies of a lupus patient during active and inactive disease.

R Suenaga1, M Evans, N I Abdou.   

Abstract

IgG anti-DNA antibodies of a lupus patient during active and inactive stages of her disease were studied. There were no significant differences in the amounts, in double-stranded DNA-binding activity, or in complement-fixing ability between purified IgG anti-DNA antibodies of both stages. However, their idiotype (Id) expressions were different as revealed by binding to rabbit anti-Ids raised against each of the anti-DNA antibodies. Moreover, the active stage anti-DNA antibodies had higher activity and less cross-reactivity with polynucleotides. Dominant anti-DNA populations during the active and inactive stages of systemic lupus erythematosus are clonally and qualitatively different.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934622     DOI: 10.1016/s0090-1229(05)80004-2

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  4 in total

1.  Cationic and high affinity serum IgG anti-dsDNA antibodies in active lupus nephritis.

Authors:  R Suenaga; N I Abdou
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

2.  Natural antibodies that react with V-region peptide epitopes of DNA-binding antibodies are made by mice with systemic lupus erythematosus as disease develops.

Authors:  F J Ward; J E Knies; C Cunningham; W J Harris; N A Staines
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

3.  Isolation of anti-nucleosome antibodies from the plasma of lupus nephritis patients.

Authors:  R Suenaga; K Mitamura; N I Abdou
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

4.  Endothelial cell binding by human polyclonal anti-DNA antibodies: relationship to disease activity and endothelial functional alterations.

Authors:  T M Chan; P M Yu; K L Tsang; I K Cheng
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.